← Leaderboards
Paul D Piehowski
Oregon Health & Science University
$1,534,630
Attributed
$4,603,890
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,603,890 · 1
By mechanism
U01$4,603,890 · 1
Top collaborators
- Brian J Druker4 shared
- Jeffrey Wallace Tyner4 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jeffrey Wallace Tyner$13,872,769
- Anupriya Agarwal$8,829,719
- Summer Lynne Gibbs$14,875,792
- Lisa M Coussens$10,998,130
- Craig Warden$1,393,094
Others in their field
Other Rising Stars on “Acute Myelocytic Leukemia”
- Michael E. Roth · Public Health Institute$8,303,012
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Kellie Bickel · Twinstrand Biosciences, Inc.$2,555,383
- Jeevisha Bajaj · University Of Rochester$2,438,184
- Bruno Di Stefano · Baylor College Of Medicine$2,398,360
- Angela Goffredo Fleischman · University Of California-Irvine$2,306,090
Research focus
Acute Myelocytic LeukemiaClinical TrialsAurora B KinaseAutomobile DrivingAzacitidineArchivesBcl2 GeneBiobankBiological MarkersBiological ProcessBiologyBiomarker ValidationCd14 GeneCd34 GeneCell Differentiation ProcessCell LineCellsCell TypeChemotherapyClinical MaterialClinical PredictorsClinical ResearchClinical TranslationCollection
Grant awards (4)
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,168,038
U01 · FY2025 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,109,637
U01 · FY2024 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,144,679
U01 · FY2023 · CA
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia$1,181,536
U01 · FY2022 · CA